癌症的基本特征包括细胞增殖、血管生成、迁移、凋亡逃避机制和细胞永生等。找到癌症发生过程中这些通路的关键标记物和对应的抗体用于检测至关重要。
为您推荐一个泛素化位点预测神器——泛素化分析工具，可以为您的蛋白的泛素化位点作出预测和评分。
细胞自噬受体图形绘图工具为你的蛋白的细胞受体结合位点作出预测和评分，识别结合到自噬通路中的蛋白是非常重要的，便于让我们理解自噬在正常生理、病理过程中的作用，如发育、细胞分化、神经退化性疾病、压力条件下、感染和癌症。
AKT2 Antibody (monoclonal) (M03)
Mouse monoclonal antibody raised against a partial recombinant AKT2.
- 产品详情
- 实验流程
- 背景知识
Application 
| WB, IF, E |
|---|---|
| Primary Accession | P31751 |
| Other Accession | M95936 |
| Reactivity | Human, Mouse, Rat |
| Host | mouse |
| Clonality | monoclonal |
| Isotype | IgG1 Kappa |
| Clone Names | 1D9 |
| Calculated MW | 55769 Da |
| Gene ID | 208 |
|---|---|
| Other Names | RAC-beta serine/threonine-protein kinase, Protein kinase Akt-2, Protein kinase B beta, PKB beta, RAC-PK-beta, AKT2 |
| Target/Specificity | AKT2 (AAA58364, 100 a.a. ~ 189 a.a) partial recombinant protein with GST tag. MW of the GST tag alone is 26 KDa. |
| Dilution | WB~~1:500~1000 IF~~1:50~200 E~~N/A |
| Format | Clear, colorless solution in phosphate buffered saline, pH 7.2 . |
| Storage | Store at -20°C or lower. Aliquot to avoid repeated freezing and thawing. |
| Precautions | AKT2 Antibody (monoclonal) (M03) is for research use only and not for use in diagnostic or therapeutic procedures. |
For Research Use Only. Not For Use In Diagnostic Procedures.
Provided below are standard protocols that you may find useful for product applications.
BACKGROUND
This gene is a putative oncogene encoding a protein belonging to a subfamily of serine/threonine kinases containing SH2-like (Src homology 2-like) domains. The gene was shown to be amplified and overexpressed in 2 of 8 ovarian carcinoma cell lines and 2 of 15 primary ovarian tumors. Overexpression contributes to the malignant phenotype of a subset of human ductal pancreatic cancers. The encoded protein is a general protein kinase capable of phophorylating several known proteins.
REFERENCES
1.Multiple defects in negative regulation of the PKB/Akt pathway sensitise human cancer cells to the antiproliferative effect of non-steroidal anti-inflammatory drugs.Lincova E, Hampl A, Pernicova Z, Star?ichova A, Kr?ma? P, Machala M, Kozubik A, Sou?ek K.Biochem Pharmacol. 2009 Sep 15;78(6):561-72. Epub 2009 May 9.
终于等到您。ABCEPTA（百远生物）抗体产品。
点击下方“我要评价 ”按钮提交您的反馈信息，您的反馈和评价是我们最宝贵的财富之一,
我们将在1-3个工作日内处理您的反馈信息。
如有疑问，联系：0512-88856768 tech-china@abcepta.com.
